首页 Invitae(usNVTA)-基本信息

Invitae(usNVTA)-基本信息

日报更新时间:04-17 11:30

周报更新时间:04-11 03:39

行情信息

今开价:39.06

最高价:39.09

成交量:2350799.0

昨收价:39.06

最低价:36.86

最新价:37.64

行情图标
概要信息

英文名称:Invitae


简介:Invitae Corporation是在特拉华州于2010年1月13日成立一个集成公司


电话:1-415-3747782


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

基因测序,一个不为人们熟知的领域,2013年,因一则新闻“安吉丽娜茱莉为防乳腺癌切除双乳(传送门)”而走进人们的视野,而为茱莉提供基因检测认为其有较大可能得乳腺癌的就是基因测序公司万基遗传(NASDAQ:MYGN)。Invitae和万基遗传是同一个领域,该行业内其他的上市公司还有:Illumina(ILMN)、上巨医疗实业(HOLX)、赛默飞世尔科技(TMO)、CareDx(CDNA)、Applied Genetic Technologies(AGTC)以及国内的A股上市公司达安基因(SZ002030)。Invitae专注于将基因序列研究,力争将全部的基因序列解秘以实现在医疗上的最大应用,帮助人们更好的享受健康的生活。Invitae对医生和患者使用实验室流程,软件工具和信息功能的集成组合处理含有患者DNA的样本,分析其特异性遗传变异信息,并生成测试报告。Invitae公司还提供一个单一的诊断服务,包括大约200个基因,主要用于与癌症有关的各种遗传性疾病检测,其他还包括心血管疾病、血液遗传疾病、神经疾病以及少儿遗传疾病。另外,NVTA还提供了家庭基因信息组成共享解决方案,只要通过一个网页或者一个APP即可实现,他使医生和患者可以查找各个基因和变体,以便找出其他的遗传基因。基因测序行业介绍:随着基因测序服务价格的下降,基因信息服务行业总额会呈指数级别增长,基因信息的生成、分析和储存获得前所未有的发展。Johns Hopkins University School of Medicine的OMM研究组的数据显示,目前发现超过4000种与基因变异相关的遗传症状,对这些基因进行测序有利于遗传病的诊断和治疗。在可预见的未来,人类将不仅为单个或者有限的几个基因测序。基因是现代医学的基石,基因测序将会造福普通大众。事实上,每个人身体上都携带一些突变基因,隐性遗传病会影响到后代的身体健康,基因突变还会影响到药物和治疗的效果。在现代医疗体系里,每个人都将拥有自己的基因信息,并且成为临床医疗的重要参考资料。根据United Health Group Inc的统计,2010年美国分子诊断市场大约是50亿美元,其中基因测序大约占60%。截止2014年12月,genetests.org估计,全球有 来自650个实验室超过40000种基因测序。预计到2021年,美国分子诊断市场将会达到90亿美元,基因测序市场份额仍会维持在60%。Invitae公司介绍:NVTA公司在旧金山有办公室和临床实验室,同时在智利的圣地亚哥有临床实验室。Invitae有一个161人组成的交叉学科团队,包括:生物信息学、临床学、遗传学,基因顾问、网页和软件工程师、图像处理师等。NVTA发展目标明确:先攻克患病者和新生儿市场,再向健康人士市场(保健、预防)进发。目标分三个阶段: 基因测序:努力促使基因测序价格降下来,同时努力做大市场。 基因管理:建立一个安全可靠的基因组管理系统,生成和储存大量的个人基因信息。 基因组网络。在获得基因信息所有者许可的前提下,我们帮助病人分享基因信息,基因信息因为分享而更有价值,将会共同促进科学和医学的发展。解决方案invitae致力于提供更加低价和便捷的基因测序服务,同时致力提供多合一基因测序服务,以提高效用价值。他们在2013年11月出售第一份基因测序报告。每一 份报告收取1500美元,客户针对性选择某种或者几种基因测序,也可以选择所有种类。截至2014年三季度末,公司为超过2000名客户提供服务,其中80%具有遗传性癌症的迹象。invitae的遗传性癌症服务有两种选择(BRCA1 和BRCA2),包含7个基因的遗传性乳腺癌基因模板、包含14个基因的遗传性结肠癌基因模板、包含17个基因的胰腺癌基因模板,或者包含29个癌症基因的整体癌症基因模板。每种服务费用都是1500美元。invitae的基因测序服务优势: 低价:一个价格包含所有测序 快速:从采样到出具报告只要三周时间 灵活:客户能自主选择测序的种类和基因模板 外延:有基因模板选择,重复领取报告 高质:NVTA基因专家团队能够制作高质量的的测序结果NVTA公司的核心理念: 患者应拥有自己的基因信息的所有权 基因信息因分享而更具有价值 医疗保健专业人士是指导和解读基因测序活动的基础 降低基因测序服务价格能够提高临床应用价值和个人效用NVTA风险提示: 公司处于发展早期的亏损状态 公司要先于市场需要投资搭建基础平台设施,若没有获得足够的测序服务订单,公司将亏损 若医疗保险没有覆盖公司的基因测序服务,那么收入和业务拓展都会受到影响 同业竞争 实验室设备和耗材采购依靠少数几家厂商,个别领域仅有单个厂商,若失去他们,有可能面临无法及时找到替代者 面临包括FDA在内的监管和一些法律问题,如果FDA将基因测序服务当做医疗设备来监管,将会对公司的业务和财务状况造成严重的影响

交易日期 交易人 职位 类型 交易份额 价格
2017-06-11 Guyer (Shelly D) Chief Financial Officer Buy 45000 --
2017-02-15 Brida (Thomas) General Counsel Sell 766 9.69
2017-02-14 Dumond (Patty) Officer Sell 1264 9.55
2017-02-14 Brida (Thomas) General Counsel Sell 794 9.54
2017-02-14 Nussbaum (Robert L.) Officer Sell 1686 9.53
2017-02-14 Bendekgey (Elias Lee) Chief Financial Officer Sell 2098 9.59
2017-02-14 Stueland (Katherine) Officer Sell 911 9.50
2017-02-12 Stueland (Katherine) Officer Buy 2152 --
2017-02-12 Brida (Thomas) General Counsel Buy 1883 --
2017-02-12 Dumond (Patty) Officer Buy 3000 --
2017-02-12 George (Sean E) Chief Executive Officer Buy 5000 --
2017-02-12 Bendekgey (Elias Lee) Chief Financial Officer Buy 5000 --
2017-02-12 Nussbaum (Robert L.) Officer Buy 4000 --
2017-02-02 George (Sean E) Chief Executive Officer Buy 176470 --
2017-02-02 Dumond (Patty) Officer Buy 44117 --
2017-02-02 Nussbaum (Robert L.) Officer Buy 58823 --
2017-02-02 Stueland (Katherine) Officer Buy 52941 --
2017-02-02 Brida (Thomas) General Counsel Buy 17647 --
2017-02-02 Bendekgey (Elias Lee) Chief Financial Officer Buy 55882 --
2016-11-21 Scott (Randal W) Chief Executive Officer Buy 66666 6.00
2016-11-17 Aguiar (Eric) Director Buy 10000 6.28
2016-11-17 Crouse (Geoffrey S) Director Buy 15000 6.25
2016-11-16 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 69074 6.00
2016-11-16 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 664259 6.00
2016-09-15 Dumond (Patty) Officer Buy 1000 3.42
2016-09-15 Dumond (Patty) Officer Buy 1000 3.42
2016-08-14 Dumond (Patty) Officer Sell 1000 8.81
2016-08-14 Dumond (Patty) Officer Buy 1000 2.82
2016-07-13 Dumond (Patty) Officer Sell 1000 8.79
2016-07-13 Dumond (Patty) Officer Buy 1000 2.82
第 页, 共 2 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Wells Fargo & Co 1156228 1.25% 1006631 672.90% 2019-03-31
SSGA Funds Management Inc 3006817 3.21% 60808 2.06% 2019-07-31
State Street Corporation 2998463 3.25% -486343 -13.96% 2019-03-31
Baker Bros Advisors LP 3902421 4.23% -- -- 2019-03-31
Wellington Management Company LLP 4029039 4.36% -154066 -3.68% 2019-03-31
Vanguard Group Inc 4238322 4.59% 898897 26.92% 2019-03-31
BlackRock Inc 5360063 5.80% 8336 0.16% 2019-03-31
Gilder Gagnon Howe & CO LLC 5530037 5.99% 572234 11.54% 2019-03-31
ARK Investment Management LLC 8729523 9.45% -40550 -0.46% 2019-03-31
BlackRock Fund Advisors 2834353 3.02% -165778 -5.53% 2019-07-31
Vanguard Investments Australia Ltd 2390829 2.55% 117988 5.19% 2019-07-31
Casdin Capital, LLC 2200000 2.38% -200000 -8.33% 2019-03-31
Goldman Sachs Group Inc 1259656 1.36% 489409 63.54% 2019-03-31
Victory Capital Management Inc. 1295205 1.38% 483590 59.58% 2019-07-31
Lord, Abbett & Co LLC 1326837 1.44% 1326837 -- 2019-03-31
Redmile Group, LLC 1374175 1.49% 848800 161.56% 2019-03-31
Northern Trust Investments Inc 1449687 1.55% 37281 2.64% 2019-07-31
AllianceBernstein L.P. 1914210 2.07% 1843810 2619.05% 2019-03-31
Wells Fargo Funds Management LLC 2180468 2.33% 423555 24.11% 2019-07-31
Perceptive Advisors LLC 2171918 2.35% 308512 16.56% 2019-03-31
Rock Springs Capital Management LP 1150000 1.25% -250000 -17.86% 2019-03-31
BlackRock Asset Management Canada Ltd 1668405 1.86% 305 0.02% 2019-05-31
Geode Capital Management, LLC 1388038 1.54% 777022 127.17% 2018-12-31
Sumitomo Mitsui Trust Holdings Inc 1094853 1.22% 1094853 -- 2019-03-31
Teachers Advisors LLC 967120 1.08% 111640 13.05% 2019-03-31
Fidelity Management & Research Company 800411 0.89% 146867 22.47% 2019-04-30
Northern Trust Corp 900768 1.00% 106274 13.38% 2019-03-31
Orbimed Advisors, LLC 824549 0.92% -450000 -35.31% 2018-12-31
Northern Trust Investments N A 794494 1.03% 7114 0.90% 2018-12-31
Deutsche Bank AG 705898 0.92% 299818 73.83% 2018-12-31
12 West Capital Management LP 800000 1.07% 800000 -- 2018-09-30
Deerfield Management Co 688062 0.92% -1213726 -63.82% 2018-09-30
BlackRock Institutional Trust Company NA 1861382 2.48% 827548 80.05% 2018-06-30
Broadfin Capital, LLC 750000 1.00% 750000 -- 2018-03-31
BlackRock Advisors LLC 809107 1.17% -770907 -48.79% 2018-10-31
PARK WEST ASSET MANAGEMENT LLC 2633910 4.91% 103017 4.07% 2017-12-31
Millennium Management LLC 536056 0.78% 468596 694.63% 2018-06-30
State Street Corp 2295925 3.33% 1546551 206.38% 2018-06-30
Daiwa SB Investments Ltd. 501847 0.73% 125322 33.28% 2018-06-30
Citadel Advisors Llc 425305 0.62% 167234 64.80% 2018-06-30
Private Wealth Partners, LLC 328400 0.48% 328400 -- 2018-06-30
Charles Schwab Investment Management Inc 322709 0.47% 158785 96.87% 2018-06-30
HighTower Advisors, LLC 366028 0.68% 45132 14.06% 2018-03-31
BNY Mellon Investment Management 185810 0.27% 51057 37.89% 2018-06-30
Northern Trust Asset Management 158185 0.23% -145 -0.09% 2018-07-31
Alyeska Investment Group, L.P. 450000 0.84% 450000 -- 2018-03-31
UBS O'Connor LLC 529466 0.99% 529466 -- 2018-03-31
FMG LLC 160000 0.24% -5000 -3.03% 2018-06-30
Morgan Stanley & Co Inc 250372 0.47% 64807 34.92% 2018-03-31
Stonepine Capital Management Llc 219022 0.41% 219022 -- 2018-03-31
Longwood Capital Partners LLC 152300 0.28% -375700 -71.16% 2017-12-31
Royce & Associates, LLC 156412 0.29% -- -- 2017-12-31
Baker Bros Advisors Llc 8399411 15.64% 1111111 15.25% 2018-03-31
Camber Capital Management LLC 2398123 4.47% -- -- 2017-12-31
Genomic Health Inc 1170663 2.85% -1037130 -46.98% 2016-12-31
TMP Associates II LP 3732460 11.69% 3732460 -- 2015-12-31
BlackRock Investment Management, LLC 808374 2.49% -23110 -2.78% 2016-10-31
Jackson National Asset Management LLC 148598 0.46% -- -- 2016-09-30
Genomic Health, Inc. 2207793 2.00% 37642871 0.10% 1999-11-30
Randal W. Scott, Ph.D 3439559 2.00% 58644481 0.10% 1999-11-30
Thomas, McNerney Partners II L.P. and affiliates 3732460 2.00% 63638443 0.10% 1999-11-30
Eric Aguiar, M.D. 3732460 2.00% 63638443 0.10% 1999-11-30
BlackRock Inc. 4166662 2.00% 71041587 0.10% 1999-11-30
Baker Brothers Life Sciences L.P. and affiliates 5050652 2.00% 86113617 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
AB Small Cap Growth Portfolio 879418 0.94% 195413 28.57% 2019-06-30
Victory RS Small Cap Growth Fund 1131430 1.21% 447030 65.32% 2019-06-30
Vanguard Extended Market Index Fund 1177063 1.26% -9882 -0.83% 2019-06-30
AB Discovery Growth Fund 1221591 1.30% 267875 28.09% 2019-06-30
ARK Genomic Revolution ETF 1888145 2.01% -41553 -2.15% 2019-06-30
iShares Russell 2000 ETF 1907423 2.04% 20659 1.09% 2019-07-30
Vanguard Total Stock Market Index Fund 2373718 2.53% 118087 5.24% 2019-06-30
SPDR 2937145 3.13% 57608 2.00% 2019-07-31
ARK Innovation ETF 5491735 5.86% -30506 -0.55% 2019-06-30
Wellington Global Health Care Equity 1110628 1.19% 15140 1.38% 2019-03-31
CREF Stock Account 336431 0.36% -180526 -34.92% 2019-05-31
iShares Russell 2000 Growth ETF 794615 0.85% 9165 1.17% 2019-07-30
EQ/AB Small Cap Growth Portfolio 393951 0.42% 34674 9.65% 2019-05-31
Fidelity 410930 0.44% -- -- 2019-06-30
Wells Fargo Small Company Growth Fund 525129 0.56% 4857 0.93% 2019-06-30
Wells Fargo Small Co Gr Port 533708 0.57% 5046 0.95% 2019-06-30
Lord Abbett Developing Growth Fund 539891 0.58% -139574 -20.54% 2019-05-31
Delaware Smid Cap Growth Fund 594143 0.63% 594143 -- 2019-06-30
TIAA-CREF Quant Small-Cap Equity Fund 658400 0.70% -10500 -1.57% 2019-05-31
Wells Fargo Discovery Fund 714298 0.76% 104800 17.19% 2019-06-30
Loomis Sayles Small Cap Growth Fund 360780 0.39% 6247 1.76% 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 1446811 1.61% -2430 -0.17% 2019-05-30
ARK Genomic Revolution Multi-Sector ETF 1712571 1.91% -95749 -5.29% 2019-04-30
SMDS Wld Impact Investment Mother Fd 354027 0.39% 189533 115.22% 2018-08-10
NT R2000 Growth Index Fund - Non-Lending 307642 0.34% 23211 8.16% 2019-03-31
State Street Russell Small/Mid Cap 287423 0.37% -- -- 2019-02-28
State Street Russell Small Cap 272499 0.35% 5943 2.23% 2019-02-28
Schwab US Small-Cap ETF 230049 0.30% -- -- 2019-03-29
Northern Trust Russell 2000 Index DC NL 167827 0.22% 575 0.34% 2019-02-28
iShares Micro-Cap ETF 167660 0.22% -- -- 2019-03-28
DaiwaSB Wld Impact Investment Mother Fd 354027 0.46% 189533 115.22% 2018-08-10
Vanguard Health Care Index Fund 148870 0.19% 8744 6.24% 2019-02-28
Wellington Global Healthcare Equity Fund 1259187 1.64% -31735 -2.46% 2018-12-31
1290 VT GAMCO Small Company Value Port 142000 0.18% -- -- 2018-12-31
BlackRock Advantage Small Cap Core Fund 138430 0.18% -7997 -5.46% 2019-01-31
UOB United Global Healthcare Fund 133158 0.17% -191220 -58.95% 2018-08-31
MFM Techinvest Technology Fund 143000 0.19% -- -- 2019-01-31
Schwab Small Cap Index Fund 128989 0.17% 3228 2.57% 2019-01-31
Alger Health Sciences Fund 132000 0.18% -10000 -7.04% 2018-11-30
Pioneer Flexible Opportunities Fund 128807 0.17% -25410 -16.48% 2018-12-31
Invesco DWA Healthcare Momentum ETF 221017 0.29% -- -- 2018-12-31
Mercer Sustainable Glbl Eq 164774 0.22% 164774 -- 2018-07-31
Royce Micro-Cap Trust 156412 0.21% -- -- 2018-06-30
BSF Americas Diversified Eq Abs Ret Fd 226537 0.30% 226537 -- 2018-07-31
Wellington Global Impact 279337 0.37% -73473 -20.83% 2018-06-30
OMGB Blackrock Global Allocation USD 257924 0.37% -138490 -34.94% 2017-07-31
BlackRock Global Allocation Fund 573694 0.83% -753953 -56.79% 2017-07-31
BGF Global Allocation Fund 257924 0.37% -138490 -34.94% 2017-07-31
EQ/GAMCO Small Company Value IB 156000 0.23% -4000 -2.50% 2018-07-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 158185 0.23% -145 -0.09% 2018-07-31
iShares Micro-Cap 170476 0.23% -- -- 2018-09-12
Vanguard Extended Market Idx Inv 775032 1.12% 19520 2.58% 2018-07-31
iShares Russell 2000 Growth 618949 0.83% -597 -0.10% 2018-09-12
Vanguard Total Stock Mkt Idx 1427573 2.07% -- -- 2018-07-31
JHancock Seaport A 143017 0.21% -10000 -6.54% 2018-07-31
Royce Micro Cap Trust 156412 0.23% -- -- 2018-06-30
BlackRock Small Cap Growth Eq Instl 129245 0.19% -9305 -6.72% 2018-07-31
State Street Russell Small/Mid Cap Idx Fd Cl I 111419 0.26% 29193 35.50% 2017-06-30
Fidelity Spartan 122521 0.18% -- -- 2018-07-31
Schwab Small Cap Index 119100 0.17% -- -- 2018-07-31
The Vanguard Russell 2000 Growth Index 115782 0.17% 2749 2.43% 2018-07-31
TETON Westwood Mighty Mites AAA 120000 0.17% -5000 -4.00% 2018-06-30
AXA 2000 Managed Volatility K 96814 0.14% -- -- 2018-07-31
CREF Stock R1 137150 0.20% 29128 26.96% 2018-06-30
RS Technology A 105675 0.15% -- -- 2018-06-30
BlackRock Extended Equity Market K 105327 0.16% 62325 144.94% 2018-06-30
BlackRock Russell 2000 90393 0.13% 32164 55.24% 2018-06-30
BlackRock Russell 2500 93167 0.14% 27290 41.43% 2018-06-30
Vanguard Instl Ttl Stk Mkt Idx InstlPls 85084 0.13% -- -- 2018-05-31
TFS Market Neutral 66444 0.15% 66444 -- 2017-07-31
Schwab Small-Cap Equity 62421 0.12% 62421 -- 2017-12-31
BlackRock Global Allocation Inv B 573694 1.32% -753953 -56.79% 2017-07-31
BlackRock Global Allocation V.I. III 435262 1.34% -- -- 2016-09-30
JNL/BlackRock Global Allocation A 148598 0.46% -- -- 2016-09-30
Transamerica BlackRock Glbl Allc VP Svc 67421 0.21% -- -- 2016-12-31
JPMorgan Small Cap Growth 295440 0.90% 1300 0.40% 2015-09-30
JNL/BlackRock Global Allocation Fd 142916 0.40% 139879 4.00% 2015-09-30
iShares Russell 2000 (AU) 118553 0.30% -75 -0.10% 2015-11-18
JPMorgan Dynamic Small Cap Growth Fund 113257 0.40% -- -- 2015-09-30
JHancock Seaport Fund 100382 0.30% 6522 7.00% 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 62640 0.20% -12140 -16.20% 2015-09-30
Trans BlackRock Glb Allc VP 62411 0.20% 5854 10.30% 2015-09-30
AZL® BlackRock Global Allocation 31581 0.10% 31073 6.00% 2015-09-30
VALIC Company II Small Cap Growth 28253 0.10% 106 0.40% 2015-09-30
Wellington Global Health Care Eq Port 446375 1.40% 102830 29.90% 2015-06-30
MassMutual Select BlackRock Global Allc 27973 0.10% 27973 -- 2015-09-30

Christine Marie Gorjanc Currently, Christine Marie Gorjanc occupies the position of Chief Financial Officer at Arlo Technologies, Inc. Ms. Gorjanc is also on the board of Juniper Networks, Inc. and Invitae Corp. In the past Ms. Gorjanc held the position of Chief Financial Officer at NETGEAR, Inc., Treasurer, VP, Controller & Assistant Secretary at Aspect Communications Corp., Tax Manager at Tandem Computers, Inc. and Manager-Tax Operations at Xidex Corp. She received a graduate degree from Golden Gate University and an undergraduate degree from the University of Texas at El Paso.
Robert Nussbaum Robert Nussbaum is Chief Medical Officer at Invitae Corp., Member of National Academy of Medicine and Member of Institute of Medicine. In his past career Dr. Nussbaum held the position of Chief-Genetic Disease Research at National Human Genome Research Institute, Member of Institute for Human Genetics & Research and Chief-Genomic Medicine Division at UCSF Medical Center. He received an undergraduate degree from Harvard College and a doctorate from Harvard Medical School.
Randy W. Scott Founder of Incyte Corp., Genomic Health, Inc. and Invitae Corp., Randal W. Scott is Executive Chairman at Invitae Corp. He is also on the board of Station X, Inc. and Freenome Holdings, Inc. He previously was Executive Chairman of Genomic Health, Inc., Chairman, President & Chief Scientific Officer at Incyte Corp. and President for Incyte Pharmaceuticals, Inc. He received an undergraduate degree from Emporia State University and a doctorate from the University of Kansas.
Elias Lee Bendekgey Currently, Elias Lee Bendekgey occupies the position of Chief Operating Officer & Secretary at Invitae Corp. and Secretary for CombiMatrix Corp. (a subsidiary of Invitae Corp.). In the past Mr. Bendekgey held the position of General Counsel at DNAnexus, Inc., Chief Financial Officer, SVP & General Counsel at Incyte Corp. and Chief Financial Officer & General Counsel at Nuvelo, Inc. He received an undergraduate degree from Kalamazoo College and a graduate degree from Stanford Law School.
Eric I. Aguiar Dr. Eric I. Aguiar is Partner at Aisling Capital LLC, Independent Director at Invitae Corp., a Member at Council on Foreign Relations, Inc. and Member-Overseers Board at Tufts University School of Medicine. He is on the Board of Directors at Invitae Corp. Dr. Aguiar was previously employed as Non-Executive Director by Amarin Corp. Plc, Partner by Thomas, McNerney & Partners LLC, a Managing Director by HealthCare Ventures LLC, Chief Executive Officer & Director by Genovo, Inc., and Executive Director by TheraTech, Inc. He also served on the board at Amarin Pharmaceuticals, Inc., CardioKine, Inc., Intuity Medical, Inc., Locus Development, Inc., Metaphore Pharmaceuticals, Inc., Oriel Therapeutics, Inc., SkinMedica, Inc. and Virdante Pharmaceuticals, Inc. He received his undergraduate degree from Cornell University and a doctorate degree from Harvard Medical School.
Sean Emerson George Sean Emerson George founded Invitae Corp. and Locus Development, Inc. Currently, he is President, Chief Executive Officer & Director at Invitae Corp. and Chief Executive Officer at CombiMatrix Corp. (a subsidiary of Invitae Corp.). Dr. George previously occupied the position of Associate for McKinsey & Co., Inc., Chief Executive Officer at Locus Development, Inc., Chief Operating Officer of Life Technologies Clinical Services Lab, Inc., Director-Strategic Planning at Molecular Probes, Inc., Vice President-Labeling & Detection Business at Invitrogen Corp. and SVP-Marketing & Life Sciences Business at Affymetrix, Inc. Dr. George received an undergraduate degree from the University of California, Los Angeles, a doctorate from the University of California, Santa Cruz and a graduate degree from the University of California, Santa Barbara.
Geoffrey S. Crouse Currently, Geoffrey S. Crouse holds the position of Chief Executive Officer for Candela Corp. Mr. Crouse is also on the board of Invitae Corp. and California Cryobank LLC. In his past career he was Executive Vice President at AMAG Pharmaceuticals, Inc., President & Chief Executive Officer at CBR Systems, Inc., Chief Operating Officer of Immucor, Inc., Director-Market Development at Roche Diagnostics Corp. and Vice President-Life Sciences Business at EMD Millipore Corp. Mr. Crouse received a graduate degree and an MBA from the University of California, Berkeley and an undergraduate degree from Boston College.
Shelly D. Guyer Presently, Shelly D. Guyer holds the position of Chief Financial & Accounting Officer at Invitae Corp. She previously occupied the position of Chief Financial & Accounting Officer for Veracyte, Inc., CFO, Executive VP-Finance & Administration at iRhythm Technologies, Inc. and VP-Business Development & Investor Relations at Nuvelo, Inc. Ms. Guyer received an undergraduate degree from Princeton University and an MBA from Haas School of Business.
Katherine Stueland Currently, Katherine Stueland occupies the position of Chief Commercial Officer for Invitae Corp. Ms. Stueland is also on the board of Rivkin Center for Ovarian Cancer and Cancan Health. In her past career Ms. Stueland was Principal at Vivo Communications, LLC and VP-Corporate Communications & Investor Relations at Dendreon Corp. She received an undergraduate degree from Miami University.
Swaroop Aradhya Swaroop Aradhya is on the board of American Board of Medical Genetics & Genomics and Head-Medical Affairs at Invitae Corp. In his past career Dr. Aradhya was Neurogenetics Director at GeneDx, Inc. He received a doctorate from Baylor College of Medicine and an undergraduate degree from Stanford University.
Robert Nussbaum Robert Nussbaum is Chief Medical Officer at Invitae Corp., Member of National Academy of Medicine and Member of Institute of Medicine. In his past career Dr. Nussbaum held the position of Chief-Genetic Disease Research at National Human Genome Research Institute, Member of Institute for Human Genetics & Research and Chief-Genomic Medicine Division at UCSF Medical Center. He received an undergraduate degree from Harvard College and a doctorate from Harvard Medical School.
Robert Nussbaum Robert Nussbaum is Chief Medical Officer at Invitae Corp., Member of National Academy of Medicine and Member of Institute of Medicine. In his past career Dr. Nussbaum held the position of Chief-Genetic Disease Research at National Human Genome Research Institute, Member of Institute for Human Genetics & Research and Chief-Genomic Medicine Division at UCSF Medical Center. He received an undergraduate degree from Harvard College and a doctorate from Harvard Medical School.
Thomas R Brida Currently, Thomas R Brida holds the position of General Counsel for Invitae Corp. He previously held the position of Associate of Orrick, Herrington & Sutcliffe LLP and Associate General Counsel at Bio-Rad Laboratories, Inc. Mr. Brida received an undergraduate degree from Stanford University and a graduate degree from Berkeley Law University of California.
Laura D'Angelo Presently, Laura D'Angelo occupies the position of Head-Investor Relations & Communications at Invitae Corp.
Chitra Nayak Chitra Nayak is on the board of Invitae Corp. In the past she held the position of Chief Operating Officer-Platform at salesforce.com, inc. and Chief Operating Officer at Funding Circle Ltd. Ms. Nayak received an MBA from Harvard Business School, a graduate degree from Cornell University and an undergraduate degree from Indian Institute of Technology Madras.

量化对比

全部评论 9

  • Invitae Corp.涨8%,软银将牵头向公司投资12亿美元。

  • Invitae Corp盘前涨超9%,软银将牵头向公司投资12亿美元。

  • 市场消息:软银将牵头向基因信息公司Invitae Corp投资12亿美元,双方将在周一发布声明。

  • 基因测序公司Invitae盘中一度涨超14%;此前“牛市女王”ARK基金创始人Cathie Wood称Invitae是她目前投资组合中最被低估的股票。

  • Invitae(NVTA.N)涨超11%,Cathie Wood称Invitae是其投资组合中最被低估的股票。

  • ARK基金创始人Cathie Wood:Invitae(NVTA.N)在分子测试领域是“最重要的公司”之一。

  • ARK基金创始人Cathie Wood:Invitae(NVTA.N)在分子测试领域是“最重要的公司”之一。

  • Invitae(NVTA.N)尾盘直线拉升,现涨3.57%。

  • 基因编辑龙头公司CRISPR Therapeutics涨超4%,生物科技公司Editas Medicines涨超3%,基因测序公司Invitae Corp.涨超6%;今日两位科学家因“开发基因组编辑方法”获得2020年诺贝尔化学奖。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐